Ad
related to: bristol-myers squibbscbn.org has been visited by 10K+ users in the past month
Search results
FDA delays decision on Dupixent in COPD; Summit makes a bold claim
BioPharma Dive via Yahoo Finance· 9 hours agoRegeneron and Sanofi now expect an FDA verdict in September. Elsewhere, Summit claimed victory over...
Bristol Myers Squibb checks 'yes' on another Prothena neurodegenerative therapy
FierceBiotech· 2 days agoBristol Myers Squibb is again dipping into the well of therapies being developed by Prothena, this...
Pharmaceutical Giant Cencora Confirms Patient Data Breach Impacting over a Dozen Pharma Companies -...
CPO Magazine· 9 hours agoU.S. pharmaceutical giant Cencora has disclosed that the February 2024 data breach leaked sensitive...
Bristol Myers Squibb Shares Cross 6% Yield Mark
Forbes· 3 days agoIn trading on Wednesday, shares of Bristol Myers Squibb were yielding above the 6% mark based on its quarterly dividend (annualized to $2.4), with the stock changing hands as low as $39.94 on ...
BMS secures another EC approval for Opdivo combination
Pharmaceutical Technology via Yahoo Finance· 2 days agoThe European Commission (EC) has granted Bristol Myers Squibb (BMS) approval for its Opdivo...
US FDA expands use of Bristol's cell therapy to treat rare blood cancer
Reuters· 1 day ago, opens new tab said on Thursday the U.S. FDA had allowed expanded use of its cell therapy for an...
The Lash Group Notifies Consumers of Massive Data Breach Leaking Their Sensitive Medical Information...
JD Supra· 4 days agoRecently, the Lash Group, a division of Cencora (formerly AmerisourceBergen) filed a series of notices with various state attorney general offices after discovering that an unauthorized party ...
Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
Zacks via Yahoo Finance· 1 day agoBristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the...
Salesforce is the most oversold stock on Wall Street amid a losing week for the markets
CNBC· 1 hour agoAll three of the major averages are on pace for losses on the week, even as Friday's reading of the...
BMS stakes $80m on Prothena’s neurodegenerative candidate
Pharmaceutical Technology via Yahoo Finance· 2 days agoFive months after being cleared for clinical trials, the global licence for Prothena’s...
